Clinical Trial Update: Tacrolimus (FK506) Study in Moderate to Severe Refractory Ulcerative Colitis Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial of tacrolimus (FK506) in moderate-to-severe refractory ulcerative colitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Tacrolimus (Tacrolimus)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Ulcerative Colitis | Phase 3 | Status: COMPLETED